ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Post-Mkt 07-30 17:13:51 EDT

1.08

+0.07

+6.93%

盘后1.08

+0.000.00%

16:10 EDT

High1.08	Low0.9700	Vol118.69K
Open1.01	D1 Closing1.01	Amplitude10.89%
Mkt Cap28.08M	Tradable Cap22.87M	Total Shares26.00M
T/O119.48K	T/O Rate0.56%	Tradable Shares21.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.08,"timestamp":1785441600000,"preClose":1.01,"halted":0,"volume":118686,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.08,"latestTime":"16:10 EDT","volume":279,"amount":301.32,"timestamp":1785442205225,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06930693069306937,"floatShares":21172300,"shares":26000400,"eps":-0.379546,"marketStatus":"Post-Mkt","change":0.07,"latestTime":"07-30 17:13:51 EDT","open":1.01,"high":1.08,"low":0.97,"amount":119482,"amplitude":0.108911,"askPrice":1.13,"askSize":1000,"bidPrice":0.9237,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.379546,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1785456000000},"marketStatusCode":4,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.01,"preHourTrading":{"tag":"盘前","latestPrice":1.01,"preClose":1.01,"latestTime":"09:16 EDT","volume":1,"amount":1.01,"timestamp":1785417418675,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.08,"latestTime":"16:10 EDT","volume":279,"amount":301.32,"timestamp":1785442205225,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.553343,"impliedVol":0.4964,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/ABVC/tweets","defaultTab":"tweets","newsList":[{"id":"2655376838","title":"ABVC Biopharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655376838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655376838?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:32","pubTimestamp":1785270745,"startTime":"0","endTime":"0","summary":"ABVC Biopharma announces special shareholder meetingABVC Biopharma will hold a virtual special shareholder meeting on Sept. 18, 2026 via Zoom.Vote planned on adopting a 2026 Equity Incentive Plan to r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLc5qyd0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027540","title":"Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654027540?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:32","pubTimestamp":1785241920,"startTime":"0","endTime":"0","summary":"New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care deliveryMALVERN, Pa., July  28, 2026  (GLOBE NEW","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334270/0/en/Greenbrook-Opens-National-Center-of-Excellence-for-Advanced-Interventional-Psychiatry-in-Rockville-Maryland.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMS","IE0031619046.USD","BK4157","BK4139","NHLD","STIM","IE00B7SZL793.SGD","LU1815336091.USD","LU0757428866.USD","ABVC","IE00B19Z4B17.USD","IE00B66KJ199.SGD","AEIS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172775791","title":"US FDA Approves Otsuka's Novel ADHD Drug Simtriyo for Market Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1172775791","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172775791?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:23","pubTimestamp":1785223420,"startTime":"0","endTime":"0","summary":"On July 27, the U.S. Food and Drug Administration (FDA) officially approved the once-daily extended-release capsule Simtriyo (centanafadine), developed by Japan's Otsuka Pharmaceutical, for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK4585","LNGR","ADHD","MEDX","BK4139","BK4588","IPOS","ABVC","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653251786","title":"Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003","url":"https://stock-news.laohu8.com/highlight/detail?id=2653251786","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653251786?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:51","pubTimestamp":1784670675,"startTime":"0","endTime":"0","summary":"An update from Helus Pharma ( ($HELP) ) is now available. Helus Pharma said on July 21, 2026 that it has completed enrollment ahead of schedule in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/helus-pharma-fast-tracks-phase-3-enrollment-for-mdd-drug-hlp003?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/helus-pharma-fast-tracks-phase-3-enrollment-for-mdd-drug-hlp003?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651910760","title":"Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651910760","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651910760?lang=en_us&edition=fundamental","pubTime":"2026-07-14 22:26","pubTimestamp":1784039193,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 with ADHD, measuring change in ADHD-RS-5 total score over 6 weeks.\nThis pediatric Phase 3 start, alongside an ongoing adolescent Phase 3 program, underscores Axsome’s push to broaden solriamfetol’s role across multiple CNS indications and age groups.\nWe’ll now examine how advancing solriamfetol...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABVC","BK4007","PTH","AXSM","BK4585","BK4139","BK4505","BK4135","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105725","title":"Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105725?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:30","pubTimestamp":1784032200,"startTime":"0","endTime":"0","summary":"Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product labeling.Qe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326843/19871/en/Supernus-Celebrates-Five-Year-Anniversary-of-Qelbree-FDA-Approval-Continuing-to-Deliver-on-Real-World-Experience-in-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","LU1169589451.USD","LU1169590202.USD","PD","PPD","BK4139","BK4585","BK4588","BK4023","BK4561","BK4121","CNS","BK4135","CDC","ADHD","ABVC","BK4530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145209","title":"Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145209","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145209?lang=en_us&edition=fundamental","pubTime":"2026-07-14 01:27","pubTimestamp":1783963620,"startTime":"0","endTime":"0","summary":"A federal appeals court revived more than 500 lawsuits that allege Tylenol and generic acetaminophen can cause attention-deficit hyperactivity disorder or autism if taken during pregnancy.The Second U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ADHD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649672519","title":"Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649672519?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:15","pubTimestamp":1783505743,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiter...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-sunosi-ip-de-risked-adhd-phase-3-expansion-supports-reaffirmed-290-12-month-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-sunosi-ip-de-risked-adhd-phase-3-expansion-supports-reaffirmed-290-12-month-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IP","ADHD","AXSM","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984983","title":"Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984983?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422000,"startTime":"0","endTime":"0","summary":"The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July  07, 2026  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopha","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323028/33090/en/Axsome-Therapeutics-Initiates-FOCUS-2-Phase-3-Trial-of-Solriamfetol-in-Children-with-Attention-Deficit-Hyperactivity-Disorder-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","ADHD","ABVC","BK4007","PTH","BK4585","AXSM","CNS","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649621431","title":"Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649621431","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649621431?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:30","pubTimestamp":1783341000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., July  06, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar TMS technology with direct patient care through","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322415/0/en/Neuronetics-to-Participate-in-a-Panel-Discussion-at-B-Riley-Securities-Mind-Muscle-Vision-Summit-on-July-16-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","BK4211","STIM","TMS","ABVC","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619008","title":"The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619008","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649619008?lang=en_us&edition=fundamental","pubTime":"2026-07-06 04:19","pubTimestamp":1783282799,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and growth indices and removed from several small-cap indices.\nThis combination of a pivotal late-stage CNS trial in a new age group and a shift into larger-cap equity benchmarks may influence how investors think about Axsome’s clinical profile and market positioning.\nWe’ll now examine how the Phase 3...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4585","AXSM","BK4007","ADHD","ABVC","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648638614","title":"ABVC Biopharma Replaces Auditor Simon & Edward with Kreit & Chiu for 2026 Audit","url":"https://stock-news.laohu8.com/highlight/detail?id=2648638614","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648638614?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:02","pubTimestamp":1783022538,"startTime":"0","endTime":"0","summary":"ABVC BioPharma replaces auditor Simon & Edward with Kreit & Chiu for 2026 auditABVC BioPharma replaced auditor Simon & Edward with Kreit & Chiu as independent accountant for fiscal 2026, effective Jun","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL92MsRh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500733","title":"Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648500733?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":"CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July  02, 2026  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321301/0/en/Cingulate-Inc-NASDAQ-CING-Added-to-Russell-3000E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","NDX","QQQJ","FTEC","QLD","BK4007","QQQY","CING","JEPQ","ONEQ","QDTE","TQQQ","QQQ","SQQQ","TECS",".IXIC","BK4139","PSQ","TQQY","QQQA","QQQE","GPIQ","ABVC","QYLG","QQQM","IYW","MNQmain","ADHD","QID","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376419","title":"BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376419","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647376419?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":"Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318863/17676/en/BrainsWay-Presents-Positive-Data-from-Largest-Real-World-Study-of-Deep-TMS-in-Patients-with-Comorbid-PTSD-and-Major-Depressive-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMS","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646952339","title":"BlinkLab Says European ADHD Study Completes Participant Recruitment, Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646952339","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646952339?lang=en_us&edition=fundamental","pubTime":"2026-06-26 13:58","pubTimestamp":1782453519,"startTime":"0","endTime":"0","summary":"BlinkLab (ASX:BB1) said its European attention-deficit/hyperactivity disorder (ADHD) study, being conducted in collaboration with Mental Care Group, completed participant recruitment and the firm's ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","BB1.AU","BK7094","ADHD","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646384202","title":"BlinkLab Nears Final Analysis in European ADHD Study After Completing Data Collection","url":"https://stock-news.laohu8.com/highlight/detail?id=2646384202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646384202?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:37","pubTimestamp":1782430675,"startTime":"0","endTime":"0","summary":"Blinklab Limited ( ($AU:BB1) ) has shared an update. BlinkLab Limited has completed recruitment and neurometric data collection for its European at...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-nears-final-analysis-in-european-adhd-study-after-completing-data-collection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-nears-final-analysis-in-european-adhd-study-after-completing-data-collection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ADHD","BK4139","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645722837","title":"Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645722837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645722837?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:05","pubTimestamp":1782227149,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Michael Okunewitch has maintained their bullish stance on DFTX stock, giving a Buy rating today. Michael Okunewitch has given h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-raises-12month-target-and-reiterates-buy-on-definium-after-best-in-class-mdd-trial-results-and-reduced-risk-adjustment-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-raises-12month-target-and-reiterates-buy-on-definium-after-best-in-class-mdd-trial-results-and-reduced-risk-adjustment-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076482","title":"Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076482?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:55","pubTimestamp":1782143746,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Francois Brisebois has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Francois Brisebois has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","DFTX","ODT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640435559","title":"Cingulate Faces FDA Delay But Maintains ADHD Drug Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640435559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640435559?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:32","pubTimestamp":1780403558,"startTime":"0","endTime":"0","summary":"Cingulate Inc ( ($CING) ) has shared an update. On June 2, 2026, Cingulate announced that the U.S. Food and Drug Administration issued a Complete R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","ABVC","BK4588","BK4139","ADHD","CING","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910025","title":"Cingulate Receives Complete Response Letter from FDA for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910025","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910025?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"No Clinical Safety or Efficacy Concerns Currently IdentifiedAgency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Wel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305119/0/en/Cingulate-Receives-Complete-Response-Letter-from-FDA-for-CTx-1301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU2237443978.SGD","CMC","LU2237443465.HKD","BK4139","CING","IE00BHPRN162.USD","ABVC","BK4585","LU2237443549.SGD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU2237443382.USD","LABU","LU2237443895.HKD","ADHD","LU0267386448.USD","LU0882574139.USD","BK4006","IE00B1BXHZ80.USD","BK4007","LU2746668461.USD","LU1363072403.SGD","LU2237443622.USD","LU0149725797.USD","LU2746668974.SGD","LU0971096721.USD","BK4588","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.1441},{"period":"1month","weight":-0.3567},{"period":"3month","weight":-0.0194},{"period":"6month","weight":-0.5},{"period":"1year","weight":-0.6611},{"period":"ytd","weight":-0.5258}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.375,"avgChangeRate":-0.130229},{"month":8,"riseRate":0.5,"avgChangeRate":-0.054488},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction